STAR-T trial of antithrombotic removal system during cardiac surgery to continue

640

CytoSorbents Corporation has received the recommendation from the independent Data and Safety Monitoring Board (DSMB) to continue the pivotal STAR-T (Safe and timely antithrombotic removal–Ticagrelor) trial as planned without any modifications, following a review of the unblinded dataset from the first 40 patients enrolled in the study

The STAR-T randomised controlled trial is a 120-patient, 30-centre pivotal study designed to evaluate the ability of DrugSorb-ATR polymer adsorption technology to reduce perioperative bleeding by removing the antithrombotic agent, ticagrelor in patients undergoing cardiothoracic surgery.

The goal of DrugSorb-ATR is to allow patients to get the critical surgery they need without delay, while reducing or preventing this bleeding risk by actively removing the drug during the surgery.

DrugSorb-ATR has received US Food and Drug Administration (FDA) breakthrough device designation for this indication. The STAR-T pivotal study is US FDA and Health Canada marketing approval for DrugSorb-ATR in this application.


LEAVE A REPLY

Please enter your comment!
Please enter your name here